BioSpace News Archive

IT-enabled healthcare ecosystems are becoming a part of integrated health care systems, with stakeholders are leveraging the systems for patient-centered care, with cost and quality.

Tiziana Life Sciences plc, a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, reports positive data from the exploratory clinical study in Brazil investigating nasally administered Foralumab, its proprietary anti-CD3 human monoclonal antibody, either alone or in combination with orally administered dexamethasone in COVID-19 patients.

The use of 2% CHG 70% IPA single use, sterile applicator skin antiseptic reduced the risk of infectious complications (catheter colonization and local infection) by 92% compared with 5% povidone iodine (PVI) 69% ethanol

Exonate, an mRNA therapy company focused on retinal diseases, announced that in collaboration with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, the first patient has been dosed with Exonate’s lead compound, EXN 407, in a Phase Ib/II clinical trial of patient volunteers with centre-involved diabetic macular oedema.

Ascentage Pharma announced that the company recently released the results from a preclinical study of APG-115, a novel MDM2-p53 inhibitor being developed by Ascentage Pharma, in the treatment of non-small cell lung cancer harboring STK11 mutations through an oral presentation on January 29, 2021, at the 2020 World Conference on Lung Cancer.

Eurofins is making new assays for the identification of B.1.1.7 and B.1.351 /B.1.1.248 variants with a one hour run time available for free to public health institutions who do not have capabilities to rapidly identify the presence of these variants.

Leading American nanomaterial and quantum dot producer and technology company, Quantum Materials Corp (OTCQB: QTMM) today announced an equity investment from California-based private equity firm, Pasaca Capital, Inc. of $15 million and under terms of the distribution agreement formed between the two companies, Q

Waters Corporation announced fourth quarter 2020 sales of $787 million, a 10% increase as reported, compared to sales of $716 million for the fourth quarter of 2019.

BioCryst Pharmaceuticals, Inc. announced that the compensation committee of BioCryst’s board of directors granted seven newly-hired employees inducement options to purchase an aggregate of 137,500 shares of BioCryst common stock on January 29, 2021 as inducements material to each employee entering into employment with BioCryst.

4Q Revenue of $1.355 billion; 68% reported growth; 65% organic growth 4Q GAAP EPS from continuing operations of $3.38; Adjusted EPS of $3.96 Initiates First Quarter and Full Year 2021 Guidance